Autopsy report · NCT06443021

Influence of Variable Inflow Volume, Dwell Duration and Glucose Concentration on Ultrafiltration Volume in APD Patients

“Internal decision”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

Fresenius Medical Care Deutschland GmbH

Sponsor type

Industry

Conditions

Renal Failure; Chronic Kidney Diseases

Interventions

PD cycler

Participants

0

Trials that died the same way

• Clinical Performance Evaluation of the Hativ P30
  “Company's internal decision.” (83% match in meaning)
• A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease
  “Internal company decision” (81% match in meaning)
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors
  “An internal business decision, not based on safety or regulatory considerations.” (69% match in meaning)
• A Phase 1 Study of ADA-011 for Subjects With Advanced Solid Tumors
  “Internal company decision (non-safety related)” (68% match in meaning)
• OLIF25™ /OLIF51™ Study
  “Business Decision” (67% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.